Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy

Summary

This randomized trial will test whether Antrodia cinnamomea supplement improves quality of life in lung cancer patients receiving platinum-based chemotherapy. Participants at Tri-Service General Hospital will be randomized to receive either Antrodia cinnamomea capsules or placebo for 3 months, with follow-up to 6 months (24 weeks). Primary outcomes include nausea/vomiting scores, sleep quality, quality of life, and cancer symptoms.

Eligibility

Inclusion Criteria:

* Pathologically and radio-graphically diagnosed lung cancer
* Age greater than 18 years
* Received platinum-based chemotherapy
* Life expectancy of six months or longer

Exclusion Criteria:

* Inability to comply with timely supplementation administration.
* Within 14 days prior to trial entry, laboratory data showing abnormal liver function, abnormal kidney function
* Within 30 days prior to trial entry, unexplained fever ≥38.5°C for 7 consecutive days or chronic diarrhea for 15 consecutive days.
* Currently receiving hormone therapy.
* Major cardiac disease or arrhythmia severe enough that the attending physician considers the patient unsuitable for trial participation.
* Major neuropathy.
* Patients with currently active acute infections.
* Patients with known allergies/allergic reactions to the investigational product or any components in their formulations.
* Patients currently taking supplements containing Antrodia camphorata extract.

Conditions3

Browse More Trials